VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

Authors
Category Primary study
JournalClinical and Experimental Rheumatology
Year 2023
This article has no abstract
Epistemonikos ID: c8925c005ca5711320d12a7e96e09f01709be4f2
First added on: Feb 15, 2025